What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · SHORT · ADMA

ADMA Biologics slapped with federal lawsuit over inflated revenue — short the fallout

ADMA Biologics just got hit with a federal lawsuit accusing the company of inflating its revenue numbers. Lawsuits like this scare investors and usually trigger a sell-off.

Idea

A federal securities lawsuit over fake revenue numbers is one of the scariest things that can happen to a stock. Even if the accusations aren't proven yet, investors tend to sell first and ask questions later. The fear and uncertainty will likely push the stock down over the coming days as people try to get out before more bad news hits.

Key details

ADMA1D#legal#short#event_driven

Community

Upvotes

Views

Copies

Cosigns

News sources

ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations — Yahoo Finance

Related ideas

Vertex drops $10B to dominate hormone treatments — ride the acquisition momentum
Amazon is eating the shipping market — short the old-school delivery giants
IBM's nightmare earnings shock — short the rip or ride the collapse

ADMA trade ideas
Latest market news